Synergistic combination comprising roflumilast and a pde-3 inhibitor
CA 2372850 C · Owner: Nycomed Asset Management Gmbh · Inventors: Kilian, Ulrich
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the combined use of the PDE4 inhibitor N- (3,5dichloropyrid-4-yl)- 3-cyclopropylmethoxy- 4-difluoromethoxybenzamide its , pharmacologically tolerable salts or its N- oxide with a PDE3 inhibitor for the treatment of certain disease conditions such as for example, acute or , chronic obstructions of the bronchi.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 27, 2000 and granted January 18, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.